hPD-1/hPD-L1
Nomenclature
C57BL/6JSmo-Pdcd1tm1(hPDCD1)Cd274tm1(hPD-L1)Smoc
Cat. NO.
NM-HU-00100
Strain State
Repository Live
Model Description
Validation Data
Fig1. The expression of human PD-1 and PD-L1 in double humanized PD-1&PD-L1 mice was confirmed by FACS.
Fig 2.Frequency of leukocyte and myeloid subpopulations in the spleen by flow cytometry
Spleen was collected from WT C57BL/6 mice and HO hPD-1/hPD-L1 mice (8-week-old, female, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the spleen. Bar indicated expressed as mean ± SEM.
Abbr. HO, homozygous; WT, wild type.
Fig 3.Frequency of leukocyte and myeloid subpopulations in the blood by flow cytometry
Blood was collected from WT C57BL/6 mice and HO hPD-1/hPD-L1 mice (8-week-old, female, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the blood. Bar indicated expressed as mean ± SEM.
Abbr. HO, homozygous; WT, wild type.
Efficacy study
Fig4. In vivo validation of double humanized PD-1&PD-L1 mice. Double humanized mice were inoculated with MC38 cells, and randomly assigned to different groups (n=8) when the tumor grew to a volume of 100 mm3. A combinatorial treatment of anti-PD-L1 and anti-PD-1 demonstrated a noticeable efficacy improvement compared to the same dose of single agent (top) without affecting the animal body weight (Bottom).
You may also like
Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
